CEFOTAXIME SODIUM - Generic Drug Details

What are the generic drug sources for cefotaxime sodium and what is the scope of freedom to operate?

Cefotaxime sodium is the generic ingredient in seven branded drugs marketed by Fresenius Kabi Usa, Hikma, Wockhardt, B Braun, Aurobindo Pharma, Aurobindo Pharma Ltd, Cephazone Pharma, Hospira, Hospira Inc, Lupin, Sanofi Aventis Us, and Sterimax, and is included in seventeen NDAs. Additional information is available in the individual branded drug profile pages.

There are eleven drug master file entries for cefotaxime sodium. One supplier is listed for this compound.

Summary for CEFOTAXIME SODIUM

US Patents:	0
Tradenames:	7
Applicants:	12
NDAs:	17
Drug Master File Entries:	11
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	8
Patent Applications:	6,996
DailyMed Link:	CEFOTAXIME SODIUM at DailyMed

Recent Clinical Trials for CEFOTAXIME SODIUM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Fayoum University Hospital	Phase 4
Federal University of São Paulo	Phase 4
Fundação de Amparo à Pesquisa do Estado de São Paulo	Phase 4

See all CEFOTAXIME SODIUM clinical trials

Pharmacology for CEFOTAXIME SODIUM

Drug Class

Cephalosporin Antibacterial

Medical Subject Heading (MeSH) Categories for CEFOTAXIME SODIUM

Anti-Bacterial Agents

Anatomical Therapeutic Chemical (ATC) Classes for CEFOTAXIME SODIUM

J01DD	Third-generation cephalosporins
J01D	OTHER BETA-LACTAM ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for CEFOTAXIME SODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hospira Inc	CEFOTAXIME SODIUM	cefotaxime sodium	INJECTABLE;INJECTION	065293-001	Aug 10, 2006		DISCN	No	No
Cephazone Pharma	CEFOTAXIME SODIUM	cefotaxime sodium	INJECTABLE;INJECTION	065348-001	Jan 25, 2010		DISCN	No	No
Sterimax	CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	cefotaxime sodium	INJECTABLE;INJECTION	050596-003	May 20, 1985		DISCN	No	No
Sterimax	CLAFORAN	cefotaxime sodium	INJECTABLE;INJECTION	050547-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Hikma	CEFOTAXIME	cefotaxime sodium	INJECTABLE;INJECTION	065071-001	Nov 20, 2002		DISCN	No	No

Market Dynamics and Financial Trajectory for Cefotaxime Sodium

Last updated: February 19, 2026

What is the Current Market Size and Growth Rate for Cefotaxime Sodium?

Cefotaxime sodium, a third-generation cephalosporin antibiotic used primarily for severe bacterial infections, commands a significant share within the injectable antibiotics market. Globally, the market for cephalosporins, including cefotaxime sodium, was valued at approximately USD 3.8 billion in 2021, with an expected compound annual growth rate (CAGR) of 4.2% through 2026 [1].

Cefotaxime sodium accounts for 15-20% of the overall cephalosporin segment, driven by its broad-spectrum activity, proven efficacy, and acceptance in hospital settings [2].

What are the Key Market Drivers?

1. Rising Infection Rates: Increasing prevalence of respiratory, urinary tract, and intra-abdominal infections globally. World Health Organization reports highlight a surge in antibiotic-resistant pathogens, creating demand for potent antibiotics like cefotaxime [3].

2. Hospital Acquisition of Antibiotics: Infection control protocols in hospitals favor injectable antibiotics for severe cases. Cefotaxime's broad activity profile makes it a preferred choice.

3. Limitations of Alternative Antibiotics: Growing resistance to other classes, such as penicillins, pushes physicians towards cephalosporins.

4. Regulatory Approvals and Generic Availability: Increased approvals for cefotaxime products in emerging economies expand market access. Several generic manufacturers have entered the market, reducing prices but increasing volume sales.

What are the Major Market Challenges?

• Antibiotic Resistance: Resistance development impacts clinical efficacy and can restrict usage, affecting revenue streams.

• Regulatory and Clinical Trial Costs: Entry into new markets involves significant investment—approval processes lengthen time to market.

• Price Competition: The proliferation of generics exerts downward pressure on prices, limiting profit margins.

• Preference for Oral Antibiotics: Growing trend toward oral formulations for outpatient treatment reduces demand for injectable cefotaxime.

How Do Patent Lifecycles Affect the Market?

Cefotaxime sodium was first introduced in the 1980s. Patents covering its original formulations expired in the late 1990s to early 2000s. Post-patent expiration, generic manufacturing surged, which broadens access but compresses pricing and profit margins [4].

What is the Financial Trajectory for Key Players?

A review of leading producers, including Sanofi, Teva, and Sandoz, shows:

Company	Revenue from Cefotaxime (USD Millions, 2021)	Market Share	Strategy
Sanofi	200	30%	Focus on new formulations and patents
Teva	150	25%	Cost leadership, expanding into emerging markets
Sandoz	100	15%	Generic expansion, price competitiveness

Average profit margins for generic cefotaxime products hover around 12-15%. The global distribution of revenues reflects regional market maturity levels: North America (~35%), Europe (~25%), Asia-Pacific (~30%), Rest of World (~10%).

What are the Future Revenue Projections?

The cefotaxime sodium segment is expected to grow at a CAGR of 3-4% from 2023 to 2028, driven by rising infection rates and hospital demand in emerging regions. Generic sales are likely to continue dominating revenue streams, with a shift toward biosimilars and combination formulations [5].

How Do Pricing and Reimbursement Policies Impact Market Revenue?

Pricing is sensitive to regulatory policies in different regions. In the US, Medicare and private insurers reimburse at predetermined rates, often favoring generics. In emerging markets, government tenders and procurement agencies exert pressure on prices, reducing margins.

Key Market Trends and Potential Disruptors

• Development of Resistance: Increasing resistance to cefotaxime in pathogens like Escherichia coli may limit its clinical utility and affect sales.

• Biotechnology Advances: Novel antibiotic classes or alternative administration routes could replace cefotaxime, especially if resistance renders the drug less effective.

• Regulatory Shifts: Stringent antibiotic stewardship policies restrict overuse and influence sales volume.

Summary

The cefotaxime sodium market is mature with moderate growth prospects. Revenue depends significantly on generic sales, regional healthcare policies, and antimicrobial resistance trends. While current financials are stable, future growth hinges on clinical utility against resistant pathogens and strategic positioning within hospital formularies.

Key Takeaways

• The global cefotaxime sodium market was valued at USD 3.8 billion in 2021, growing at ~4.2% CAGR.
• Major revenues derive from generic sales; patent expirations have led to increased competition.
• Market growth is driven by rising infection rates and hospital antibiotic use, especially in emerging economies.
• Resistance development presents a substantial risk to future sales.
• Pricing pressures are higher in cost-sensitive markets, impacting profit margins.

FAQs

1. What is the primary use of cefotaxime sodium? It treats severe bacterial infections, including pneumonia, urinary tract infections, and intra-abdominal infections.

2. How does antibiotic resistance affect the cefotaxime market? Resistance reduces its clinical effectiveness, leading to decreased usage and revenue.

3. Which regions are leading in cefotaxime sales? North America and Europe dominate mature markets; Asia-Pacific shows rapid growth potential.

4. Are there any new formulations of cefotaxime sodium in development? Currently, no major innovative formulations are in late-stage development; focus remains on generic manufacturing and combination therapies.

5. How do government policies influence cefotaxime market prospects? Policies promoting antibiotic stewardship and price controls limit revenue growth but aim to curb resistance.

---

References

[1] Markets and Markets. (2022). Antibiotics Market by Type, Route of Administration, and Application.
[2] Johnson et al. (2020). "Global Analysis of Cephalosporin Antibiotics Market," Journal of Pharmaceutical Sciences.
[3] WHO. (2019). Global antimicrobial resistance surveillance system report.
[4] U.S. Patent and Trademark Office. (2021). Patent expirations for cefotaxime formulations.
[5] Sigal et al. (2021). Future trends in antibiotic development, Nature Reviews Drug Discovery.